Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lenalidomide works in treating patients with acute
myeloid leukemia that have had a decrease in or disappearance of signs and symptoms of
cancer, although cancer still may be in the body and may be likely to come back or spread.
Biological therapies, such as lenalidomide, use substances made from living organisms that
may kill cancer cells by blocking blood flow to the cancer and by stimulating white blood
cells to kill the cancer cells.